GLP-1 therapy for sustainable weight loss.
Physician-prescribed semaglutide (Wegovy) and tirzepatide (Mounjaro) with lab monitoring, video consults, and peptide support to protect lean muscle. Not a questionnaire — a real medical relationship.
Start your weight loss consultHow GLP-1 therapy works.
Appetite suppression
GLP-1 receptor agonists mimic your body's natural incretin hormones, signaling fullness to the brain. Patients report significantly reduced hunger and fewer food cravings within the first 2-4 weeks of treatment.
Insulin sensitivity
GLP-1s enhance your pancreatic beta-cell response, improving how your body processes glucose. This reduces blood sugar spikes after meals and helps break the cycle of insulin resistance that drives fat storage.
Metabolic reset
Over 12-16 weeks, GLP-1 therapy shifts your metabolic set point. Gastric emptying slows, reducing caloric absorption. Combined with physician-guided nutrition, patients achieve sustainable body composition changes — not just water weight.
FDA-approved GLP-1 medications.
Semaglutide
Wegovy / Ozempic
GLP-1 receptor agonist
In the STEP 1 clinical trial, patients lost an average of 14.9% of body weight over 68 weeks compared to 2.4% with placebo. STEP 3 showed 16% weight loss when combined with intensive behavioral therapy.
FDA-approved for chronic weight management in adults with BMI ≥ 30 (or ≥ 27 with a weight-related comorbidity). Dose is titrated over 16-20 weeks to minimize GI side effects.
Tirzepatide
Mounjaro / Zepbound
Dual GIP/GLP-1 receptor agonist
The SURMOUNT-1 trial demonstrated up to 22.5% body weight loss at the highest dose over 72 weeks — the most significant weight reduction achieved by any anti-obesity medication to date.
FDA-approved for type 2 diabetes (Mounjaro) and chronic weight management (Zepbound). The dual-agonist mechanism provides additional metabolic benefits beyond GLP-1 alone.
Why patients choose KAYU for GLP-1 therapy.
Physician video consult
You speak face-to-face with a board-certified physician — not a chatbot, not a questionnaire. Your doctor reviews your labs, medical history, and goals before prescribing anything.
Lab-driven protocols
We order comprehensive metabolic panels, thyroid function, and insulin markers before starting. Your dose is titrated to YOUR biology, with labs rechecked at 8 and 16 weeks.
AI-assisted monitoring
Between consults, KAYU's AI tracks your progress, flags concerning trends, and adjusts recommendations in real time. Your physician reviews every alert.
Muscle preservation support
GLP-1 therapy can cause lean mass loss. KAYU pairs your protocol with targeted peptides (BPC-157 for gut health, sermorelin for GH support) and protein guidance to protect muscle.
No hidden fees
Your monthly membership covers physician consults, lab orders, AI monitoring, and ongoing protocol adjustments. Medication cost is separate and transparent.
Everything except the medication itself
- Initial physician video consultation
- Comprehensive lab panel with results review
- GLP-1 prescription (medication cost billed separately by pharmacy)
- Ongoing AI-assisted progress monitoring
- Monthly physician check-in
- Peptide support protocol (BPC-157, if clinically appropriate)
- Unlimited secure messaging with your care team
GLP-1 therapy FAQ.
Who is eligible for GLP-1 therapy?
GLP-1 medications are FDA-approved for adults with a BMI of 30 or higher, or a BMI of 27+ with at least one weight-related condition (hypertension, type 2 diabetes, high cholesterol, sleep apnea). Your KAYU physician makes the final determination based on your full medical history and lab results.
What are the common side effects?
The most common side effects are gastrointestinal — nausea, constipation, and diarrhea — typically during dose escalation. KAYU mitigates this with slow titration schedules and supportive medications when needed. Most patients report side effects diminish significantly by week 8.
How quickly will I see results?
Most patients notice appetite reduction within the first 1-2 weeks. Measurable weight loss typically begins by week 4-6 and accelerates through months 3-6 as you reach your maintenance dose. Clinical trials show peak weight loss at 12-18 months of consistent use.
Will I gain the weight back if I stop?
Studies show that some weight regain occurs after discontinuation. KAYU addresses this by building sustainable habits during treatment, monitoring metabolic markers, and designing a gradual taper protocol rather than abrupt cessation. Some patients transition to maintenance doses long-term.
How does KAYU help preserve muscle mass?
Rapid weight loss can reduce lean muscle. Your KAYU physician prescribes targeted protein intake (typically 1g per pound of goal body weight), may add peptide support (sermorelin for GH release, BPC-157 for recovery), and monitors lean mass via body composition tracking.
Can I use HSA or FSA funds?
Yes. GLP-1 medications prescribed for a medical diagnosis (obesity, type 2 diabetes) are eligible for HSA and FSA reimbursement. KAYU provides the documentation your benefits administrator needs.
What if GLP-1 therapy isn't right for me?
Your physician may recommend alternative approaches — thyroid optimization, metabolic peptides, or hormone balancing — depending on your labs. KAYU never prescribes GLP-1 when the root cause is something else entirely. If you're not a candidate, we tell you why and what we'd do instead.
Is this compounded semaglutide?
KAYU prescribes brand-name, FDA-approved medications (Wegovy, Ozempic, Mounjaro, Zepbound) dispensed by licensed pharmacies. We do not prescribe compounded semaglutide or tirzepatide. Your safety is non-negotiable.
Ready to feel rooted?
Two minutes to the assessment. One week to your first consult. A protocol built on your bloodwork from a physician who knows your name.